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Abstract:  81 
Cervical cancer is widely preventable through screening, but little is known about the duration of 82 
protection offered by a negative screen in North America. A case-control study was conducted with 83 
records from population-based registries in New Mexico. Cases were obtained from the Tumor 84 
Registry diagnosed with cervical cancer in 2006-2016. Five controls per case from the New Mexico 85 
HPV Pap Registry were matched to cases by sex, age and place of residence. Dates and results of all 86 
cervical screening and diagnostic tests since 2006 were identified from the pap registry. We 87 
estimated the odds ratio of non-localized (stage 2+) and localized (stage 1) cervical cancer associated 88 
with attending screening in the 3yrs prior to case-diagnosis compared to women not screened in 89 
5yrs. Of 876 cases, 527 were aged 25-64y with ≥3yrs of potential screening data. 38% of cases and 90 
61% of controls attended screening in a 3yr period. Women screened in the 3yrs prior to diagnosis 91 
had 83% lower risk of non-localized cancer (odds ratio (OR)=0.17,95%CI:0.12-0.24), and 48% lower 92 
odds of localized cancer (OR=0.52,95%CI:0.38-0.72), compared with women not screened in the 5yrs 93 
prior to diagnosis. Women remained at low risk of non-localized cancer for 3.5-5yrs after a negative 94 
screen compared to women with no negative screens in the 5yrs prior to diagnosis. Routine cervical 95 
screening is effective at preventing localized and non-localized cervical cancers; 3-yearly screening 96 
prevents 83% of non-localized cancers, with no additional benefit of more frequent screening. 97 




Cervical cancer is largely preventable, yet an estimated 13,170 women in the United States 100 
(US) will be diagnosed with invasive cervical cancer in 2019, an age-standardized rate of 7.6 per 101 
100,000 women in 2011-161.  Cervical screening and human papillomavirus (HPV) vaccination are 102 
two methods of preventing cervical cancer. In 2012 consensus guidelines were issued for cervical 103 
screening in US populations, recommending screening begin at age 21yrs; 3-yearly cytology for 104 
women aged 21-29yrs, and either 3-yearly cytology or 5-yearly co-testing (co-occurring HPV and 105 
cytology testing) for women 30-64yrs2, 3. In 2018 the US Preventive Services Task Force (USPSTF) 106 
released updated guidelines, adding 5-yearly primary HPV testing as an option for women aged 30-107 
65yrs4. Most women aged >65yrs can cease cervical screening2, 4. The first HPV vaccine was licensed 108 
in the US in 20065 and the Centers for Disease Control and Prevention first recommended routine 109 
HPV vaccination for girls aged 11-12yrs in 20076. 110 
Screening has been shown to be effective at preventing cervical cancer on a population level 111 
since the 1960s7. Although the effectiveness of screening has been evaluated in numerous European 112 
populations7-13, the sensitivity of cytology varies between screening settings14. Previous research on 113 
the effectiveness of cervical screening within the US has focused on women enrolled in health plans 114 
or integrated health systems15, 16, and/or has focused on women of specific ages17. In 2006 HPV was 115 
added to the list of reportable conditions for individuals residing in New Mexico. All cervical 116 
screening test results (HPV, Pap cytology and co-testing) and all pathology for the cervix, vagina and 117 
vulva are reported to the New Mexico HPV Pap Registry (NMHPVPR)18. The NMHPVPR has previously 118 
been described in detail19. New Mexico is the only State in the US with a complete record of all 119 
cervical screening, diagnosis and treatment, providing appropriate high-quality data to evaluate the 120 
effectiveness of cervical screening on a population basis, across a variety of diverse healthcare 121 
delivery settings and populations.  The population of New Mexico is diverse; according to 2018 122 
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population estimates, 49.1% of the population were of Hispanic or Latino origin, 10.9% were 123 
American Indian or Alaska natives, and 2.6% were African American20.  124 
We assessed the effectiveness of cervical screening in New Mexico using a case-control 125 
study design. We addressed three questions (outlined in the Methods) which together provide 126 
insights into the effectiveness of screening on a state-wide basis. This study was approved by the 127 
University of New Mexico Human Research Review Committee.  128 
Methods 129 
Cervical Cancer Cases 130 
We collected data on all cervical cancer diagnoses in the population-based New Mexico 131 
Tumor Registry (NMTR) during 2006-2016. For each case, the NMTR provided information on the 132 
month/year of birth, month/year of diagnosis, morphology and stage at diagnosis (using the derived 133 
AJCC-6 stage classification system). NMTR records were linked with the NMHPVPR to provide 134 
information on each case’s history of cervical screening, diagnostic and treatment results within New 135 
Mexico since January 2006. The reason why each test was performed was not available; see 136 
Supplementary Materials 1 (SM1) for details on how we determined which tests were likely due to 137 
symptoms. Only colposcopy procedures resulting in a biopsy were captured. With few exceptions, 138 
information was available for each woman’s census tract of residence at cancer diagnosis and at 139 
each screening or diagnostic test.  140 
Since cancers histologically diagnosed within 5 months of an abnormal screening result were almost 141 
certainly present at the time of the screen, and in most cases will have been screen-detected, we 142 
took the date of the first abnormal cytology or positive HPV test within 5 months of histological 143 
diagnosis as the “date of index diagnosis”. The date of index diagnosis for cases with no such 144 
abnormal test result was the date of diagnosis. We note that this definition primarily affects results 145 
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when considering “time since last screen” since this definition does not count a positive test less 146 
than five months before histological diagnosis as a pre-diagnostic test.  147 
Controls 148 
Controls were selected from the NMHPVPR.  Five women were selected per case, matched on date 149 
of birth and census tract of residence at diagnosis. To be eligible as a control, women had to be alive 150 
without a known hysterectomy or diagnosis of cervical cancer recorded at the date of the case’s 151 
diagnosis. Since women were only in the NMHPVPR if they had attended screening from January 152 
2006-December 2016, we added a fractional number of unscreened “virtual-controls” for each case, 153 
to represent women who had not attended screening between January 2006-December 2016, and 154 
were therefore not in the NMHPVPR. The number of virtual controls was determined by comparing 155 
numbers of women in NMHPVPR with numbers from the census. Details on how the weights were 156 
calculated to determine the fractional number of unscreened women are available in SM2, and 157 
additional details on matching in SM3. All controls were assigned their matched case’s date of 158 
diagnosis as a date of pseudo-diagnosis.    159 
Measures to evaluate the effectiveness of cervical screening 160 
We address the following primary questions:  161 
1) What is the risk of (i) stage 1 (localized), and (ii) stage 2+ (non-localized) cervical cancer 162 
within 3 years of attending screening compared with the risk in women who did not 163 
attend screening within the previous 5 years?  164 
2) For how long do women remain at lower risk of non-localized cancer after a negative 165 
screen?  166 
3) How does the risk among women who attend screening frequently (at least once every 167 
2.5 years), regardless of the screening result, compare with the risk among women who 168 
do not attend screening, or who attend infrequently?  169 
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We examined the effect of attending screening on the risk of cervical cancer using the 170 
following measures to answer each question. 1) Existence of a satisfactory screen in the 3yrs prior 171 
(versus none in the 5yrs prior) to the case’s date of index diagnosis. This analysis was restricted to 172 
women with ≥3yrs of potential pre-diagnosis screening history. 2) Time between the last negative 173 
screening test and the case’s date of index diagnosis, among women with ≥5 years of screening 174 
history available. A screening test was defined to be negative if there was a negative cytology or HPV 175 
test which was not taken as part of a positive co-test, nor was it the first negative cytology/HPV test 176 
within 12 months of an abnormal screening test. We used the following categories: ≤1.5yrs, 1.5-177 
2.5yrs, 2.5-3.5yrs and 3.5-5yrs, compared with women with no recorded negative screening tests 178 
within 5 years of the case’s date of index diagnosis. 3) We defined a woman to have been frequently 179 
screened if she had at least 2 screens a minimum of 10 months apart, with no interval >30 months 180 
between screens, in the 5yrs prior to the date of indexdiagnosis/pseudo-diagnosis. Women with 181 
some screening in the 5yrs prior to the date of index diagnosis who did not meet the criteria of 182 
frequent screening were considered to have attended screening infrequently. This analysis was 183 
restricted to women with at least 5yrs of screening history, to allow us to distinguish unscreened 184 
from infrequently screened women. 185 
Since women are only recommended to attend routine screening until age 65yrs, we restrict 186 
the main analyses to women aged 25-64yrs. Except where explicitly stated otherwise, when analyses 187 
considered screening in a 5yr period, we excluded cases and their matched controls diagnosed 188 
before 1st January 2011. All analyses were carried out for all stages combined and separately by 189 
stage at diagnosis. 190 
We carried out seven sensitivity analyses on the first question addressed (What is the risk of 191 
(i) stage 1 (localized), and (ii) stage 2+ (non-localized) cervical cancer within 3 years of attending 192 
screening compared with women who did not attend screening within the previous 5 years?). The 193 
first sensitivity analyses (SA1) adjusted for the census-tract level sociodemographic variables shown 194 
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in Table S1, since the controls were matched to the cases on census tract, and we do not have 195 
individual-level sociodemographic data. SA2 excluded women whose address was a P.O. Box or zip 196 
code (see SM3). SA3 used an alternative set of weights, where control women from the NMTR who 197 
were diagnosed with potentially screen-detected cancers (breast or colorectal) were excluded when 198 
calculating the weights. SA4 excluded the virtual (unscreened) controls from the analysis, to examine 199 
the impact of merely selecting controls from the NMHPVPR, without allowing for the fact that it is 200 
not a population register, and that women who did not attend screening from January 2006-201 
December 2016 could not be selected as a control. SA5 included women of all ages, regardless of 202 
whether they were recommended to attend screening, and SA6 included women aged 25-69y, since 203 
65y was only introduced as the upper age limit of screening in 2012 3. Finally, SA7 used a reference 204 
category of women who had not attended screening in a 3-year period, rather than a 5-year period. 205 
Statistical Methods  206 
We present results from unadjusted weighted logistic regression analyses (having broken 207 
the matching, to allow for the weights) as the primary results. 208 
Results 209 
A total of 876 women were diagnosed with cervical cancer in New Mexico between 1st 210 
January 2006 and 31st December 2016. Of these 876 cancers, 70% were squamous, 19% 211 
adenocarcinoma, 2% adenosquamous and 8% other morphologies. A total of 646 women were 212 
diagnosed from January 2009-December 2016, with ≥3yrs of potential screening history recorded. Of 213 
these, 47.9% were diagnosed at ages 35-54yrs, with only 2.3% (N=15) diagnosed before age 25yrs, 214 
and 15.8% (N=102) diagnosed aged ≥65yrs (Figure 1, Table 1). The stage at diagnosis was strongly 215 
related to age at diagnosis; in women <35yrs, 75.0% with a known stage were stage 1, compared to 216 
41.1% among women aged ≥65yrs.  217 
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Approximately 40% (38.0%) of cases diagnosed aged 25-64yrs attended screening in the 3 218 
years prior to the date of index diagnosis (Table 2), compared with 61.2% of controls (weighted for 219 
women without a record of screening in the NMHPVPR). Women aged 25-64yrs who attended 220 
screening in a 3yr period had a lower risk of diagnosis for each cancer stage compared to women not 221 
screened in the last 5yrs (Table 2, S2). 22.5% of women with stage 3+ cancer had been screened in 222 
the 3yrs prior to the date of index diagnosis, compared to 59.3% of women with stage 1A cancer 223 
(Table S2). The effect of attending screening in the last 3yrs increased with increasing cancer stage, 224 
from no effect on the odds of stage 1A cancer (odds ratio (OR)=0.78, 95%CI:0.48-1.28) to strong 225 
effects on stage 3+ cancer (OR=0.16, 95%CI:0.10-0.23) compared to women who did not attend in 226 
the last 5yrs. Figure 2 shows there were effects of screening on non-localized cancers for all ages, 227 
but only for ages 35-49yrs and 50-64yrs for stage 1 cancers.   228 
The results from sensitivity analyses (SA) are presented in Figure S1. Most of the SA 229 
provided extremely similar results, more details are provided in SM4. When we assumed that the 230 
population at risk of cervical cancer excluded women with a hysterectomy (who guidelines have 231 
recommended against screening since 20122), and that all hysterectomized women had not 232 
attended screening, the proportion of unscreened women was 0 for women aged 20-69. This is 233 
equivalent to SA4, when the virtual-controls were excluded from the analyses; this sensitivity 234 
analysis showed a larger effect of screening (SA4).    235 
For time since the last negative screen (Table 3), when restricted to women with ≥5yrs of 236 
potential screening history, women aged 25-64yrs with a negative screen remained at lower risk of 237 
both stage 1 (OR=0.20, 95%CI:0.14-0.28) and non-localized cancer (OR=0.11, 95%CI:0.07-0.17) for at 238 
least 3.5yrs compared to women with no negative screening in the last 5yrs (a mix of women with no 239 
screening and those with only abnormal screening results). The risk for stage 2+ cancers remained 240 
constant over the first 3.5yrs. Results were similar in the sensitivity analyses, adjusting for census-241 
level socioeconomic variables, and using alternative weights (Table S3). There was a significant 242 
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reduction in risk of non-localized cervical cancer for at least 3.5yrs following a negative test relative 243 
to women with no negative tests in 5yrs for women in each age group considered (25-34yrs, 35-244 
49yrs, 50-64yrs, ≥65yrs), except stage 1 for women aged ≥65y (Figure S2). In sensitivity analyses, 245 
when the analysis was extended to women with ≥3yrs potential screening history rather than 5yrs, 246 
the results were very similar (Table S4). 247 
Women who attended screening frequently (at least 2 screens a minimum of 10 months 248 
apart, with no interval >30 months between screens) were at significantly lower risk of both non-249 
localized (OR=0.10, 95%CI:0.05-0.19) and stage 1 cancer (OR=0.43, 95%CI:0.28-0.65) than women 250 
who did not attend screening in a 5yr period (Table 4). Women who attended screening in the 251 
previous 5yrs, but did not meet the criteria for frequent screening (‘ infrequently’ screened) were at 252 
significantly reduced risk of both non-localized (OR=0.26, 95%CI:0.18-0.37) and stage 1 cancer 253 
(OR=0.58, 95%CI:0.40-0.82) compared with women not screened in 5yrs, but at significantly greater 254 
risk of non-localized cancer compared with those screened frequently (OR=2.54, 95%CI:1.33-4.84). 255 
Sensitivity analyses produced very similar results (Table S5). When restricted to women who 256 
attended screening in the 2.5yrs prior to the date of index diagnosis or who had not attended in 257 
5yrs, the results were also very similar (Table S6). 258 
When restricted to women who had only cytology screening (i.e. no HPV tests prior to 259 
diagnosis), results of the 3 main analyses were very similar (Tables S7-S9).  260 
Discussion 261 
This study addressed three key relevant questions related to the performance of cervical 262 
screening. First, attending screening within a 3yr period reduced the odds of non-localized cancer by 263 
83%, and stage 1 cancer by 48% compared to women not screened in 5 years. Second, women who 264 
had a negative screening test were at much lower risk of both non-localized and stage 1 cancer for 265 
up to 5yrs compared to women without a negative screen in the last 5yrs, with a larger benefit in the 266 
first 3.5yrs. Third, frequently attending cervical screening (at least 2 screens a minimum of 10 267 
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months apart, with no interval >30 months between screens) was associated with a 90% reduction in 268 
the odds of non-localized cervical cancer, and a 57% reduction in the odds of stage 1 cervical cancer, 269 
compared to women who did not attend screening for 5yrs.  Notably, we found similar relative 270 
benefits of screening at ages 25-34yrs, 35-49yrs, 50-64yrs, and aged ≥65yrs for non-localized cancer.  271 
It is important to acknowledge that cancers diagnosed before symptoms developed should 272 
be considered a success of cervical screening; 23% of cancers diagnosed at a known stage in New 273 
Mexico 2006-16 were diagnosed at stage 1A.  The stage distributions of cervical cancers diagnosed in 274 
New Mexico over the study time period including stage 1A were very similar to that computed for 275 
SEER18 registries overall (SEER*Stat November 2018; data not shown).  276 
Women who were screened at least once every 2.5yrs (‘frequently’) had a relative risk of 277 
non-localized cancer of 0.39 compared with women screened infrequently. This was also the case 278 
when restricted to women who were screened within the 2.5yrs prior to the date of index diagnosis, 279 
indicating that this is not purely due to the presence of a recent test, but to having had multiple tests 280 
in the 5yr period. This was largely a study of cytology, with little co-testing. The sensitivity of 281 
cytology for CIN2+ is around 71-75%21; therefore there is an advantage to having more frequent 282 
screenings, due to the high level of false negatives for a single cytology test. However, this does not 283 
mean that annual testing is an improvement, as demonstrated by the very similar risk of non-284 
localized cancer 0-1.5yrs after a negative screen compared with 2.5-3.5yrs after a negative screen. 285 
On the contrary, while this study was not designed to assess the disadvantages of screening more 286 
frequently than current guidelines recommend, there are many reasons to dissuade this practice. 287 
First, more frequent screening increases the probability of having a false-positive test (when either 288 
no precancerous lesion is present, or the precancerous lesion would regress without requiring 289 
intervention). Second, false-positive rests have the potential to increase stress and anxiety if further 290 
diagnostic testing is required, in addition to the discomfort from a colposcopy. Additionally, there is 291 
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the time and expense associated with unnecessary testing; in New Mexico 28% of women who 292 
reside in rural areas must travel more than 30 minutes each-way to seek diagnostic services22.     293 
Recent guidelines recommend routine HPV co-testing in women aged 30-65yrs4. The 294 
majority of screening records in New Mexico in 2006-2016 were cytology tests taken alone, though 295 
the proportion of HPV tests or co-tests increased with time (from 4.2% in 2006 to 54.7% in 2016), 296 
and when restricted to women aged 30-65yrs, where co-tests are routinely recommended, 67.8% 297 
were observed in 2016. Co-testing will increase the sensitivity of a single round of screening, and 298 
potentially support longer screening intervals versus intervals when screening by cytology alone23. 299 
Whether longer screening intervals can be successfully adopted by the US in the absence of 300 
organized call-recall systems should be given careful consideration. As cervical screening intervals 301 
lengthen for primary HPV testing and co-testing over time, it will be critical to monitor the 302 
proportion of women who fail to rescreen at 5 year intervals.  Although HPV-based technologies are 303 
directed at improving screening efficiencies and reducing potential harms from screening, 304 
lengthening cervical cancer screening intervals in the US may not be readily implemented due to the 305 
lack of organized screening programs. Furthermore, the continuously changing landscape of cervical 306 
screening could result in an increase in cervical cancer incidence if women fail to return for screening 307 
or return beyond the duration of protection afforded.  308 
Whilst we have shown that cervical screening in New Mexico is effective at preventing 309 
cervical cancer, only 61% of controls aged 25-64yrs had attended cervical screening in a 3yr period. 310 
Therefore, initiatives which increase screening coverage are likely the best investment for improving 311 
the prevention of cervical cancer, especially among women from birth cohorts which did not benefit 312 
from HPV vaccination prior to sexual initiation. Since not all attendees return for their next screen, it 313 
is important to use the most sensitive screening test available.  314 
Similar methods have been used to explore the effectiveness of cervical screening in 315 
Europe8-11, 24, 25 and Australia26.  Andrae et al8 found a slightly lower effect of screening in women 316 
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aged 30-65 in Sweden for all stages (OR=2.52) and stage 2+ (OR=4.82), when considering women 317 
who weren’t screened compared to women who were screened in the recommended interval (3-318 
yearly for women aged 30-50 and 5-yearly for women ages 50-60). Yang et al26 found that even 319 
infrequent screening in Australia, defined as a pap test in only one year of a four year period, was 320 
associated with an 85% reduction in risk of all stages of cervical cancer, and frequent screening (a 321 
pap in at least two years in a four year period) was associated with around a 95% reduction in risk. 322 
These effects are slightly larger than those found for infrequently and frequent screening in our 323 
study, though our definition of frequent screening differs slightly.  324 
New Mexico is the only state within the US where cervical screening data of this quality exist 325 
on a population basis, enabling the evaluation of cervical screening as practiced across a wide range 326 
of healthcare delivery settings. Screening recommendations and implementation approaches vary 327 
widely between countries27, so results from one setting may not apply to another; for example, in 328 
the US the vast majority of screening is opportunistic whereas in Sweden there is a national program 329 
where women are invited for screening28. The importance of comprehensive audits of screening 330 
programs including the full target population is widely recognized29, 30. Previous research on the 331 
effectiveness of cervical screening in the US has relied on data from women enrolled in health plans 332 
or integrated health systems15, 16 who may be at different risk of cervical cancer than the general 333 
population.  Screening guidelines for the US have been almost exclusively based on the analysis of 334 
cervical screening data which are not representative of women and/or providers in the general 335 
population2, 31. Furthermore, studies of cervical screening effectiveness in the US have been 336 
conducted in settings where screening is implemented by system-specific screening guidelines. For 337 
example Kaiser Permanente Northern California introduced HPV as part of a co-test in 200332, 338 
whereas HPV co-testing did not even begin utilization in mainstream clinical practice in New Mexico 339 
until 2013, following national cervical screening guidelines issued in 20123.  340 
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It was not possible to select controls from a population register and link to their screening 341 
history. Only women who have attended screening at least once could be identified from the 342 
NMHPVPR; it was therefore important to augment this with virtual-controls (who had not been 343 
screened since January 2006) based on the census. Had we not included virtual-controls, we would 344 
have overestimated the impact of screening. We weighted the controls selected from the NMHPVPR 345 
by identifying the age-specific proportion of matched women in the NMTR who had a screening 346 
record in the NMHPVPR. However, women who develop non-cervical cancer may have different 347 
screening behaviors compared with the general population; we therefore re-weighted the controls 348 
excluding women diagnosed with cancers which could have been screen-detected (breast and 349 
colorectal), and the results were extremely similar (Figure S1, Tables S3, S5). Our results estimated 350 
75% of controls aged 25-65yrs had been screened in the past 5 years; this is consistent with previous 351 
investigations which estimated the 5-year screening coverage for women aged 21-65yrs in New 352 
Mexico to be around 80%19.   353 
Whilst we have not included any woman who we know to have had a hysterectomy, we only 354 
have incomplete information on hysterectomies (particularly prior to 2006). The situation is further 355 
complicated in that prior to 2012, the majority of women with a hysterectomy were still offered 356 
screening. If we add together the number of women in the screening registry with the number of 357 
women in New Mexico who have had a hysterectomy, the sum, in most age-groups, is greater than 358 
the number in the census. Analysing the data in this way would be equivalent to not allowing for 359 
unscreened (virtual) controls – it makes screening appear better than it is. 360 
We have used the date of the first abnormal cytology or positive HPV within 5 months of 361 
diagnosis as the date of index diagnosis rather than the definitive date of diagnosis used by the 362 
NMTR33, and considered screening in a 3- or 5yr period prior to this date. We only have records of 363 
screening tests performed on women where addresses were recorded as a resident of New Mexico 364 
or which were taken from a New Mexico provider; whereas some women may have attended 365 
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screening in other States which would have been missed.  Some of the women selected as 366 
NMHPVPR controls may only have been resident in New Mexico for a limited period, for example 367 
due to migration, therefore our data may not represent their full screening history since 2006. When 368 
limiting the analyses to women diagnosed with cervical cancer at age 25-64yrs who had at least 5yrs 369 
of screening history data, our sample was reduced to 410 cases. Screening guidelines varied both 370 
between and within organizations across the period of this study, so we could not evaluate the 371 
effect of screening among women who complied with screening guidelines. We have not linked HPV 372 
vaccination status to screening histories, but this is likely to have minimal impact on our results due 373 
to the long natural history from HPV infection to cervical cancer versus the introduction of HPV 374 
vaccination. We do not have sufficient women who were only screened using HPV testing to 375 
compare the effect of screening using cytology alone to those with HPV testing, nor sufficient 376 
numbers of women with adenocarcinomas who have at least 3 years of screening data when broken 377 
down by stage and screening history in order to investigate the effect of screening by histologic 378 
subtype.   379 
In conclusion, our study demonstrates that routine screening at a population level has had a 380 
beneficial effect in preventing cervical cancer. However, only 61% of controls in this study had 381 
attended screening in a 3yr period. Thus, increasing screening coverage will have the greatest impact 382 
in achieving further reductions in cervical cancer rates.   383 
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